Prostatype Genomics AB (PROGEN) — Capital Reinvestment Ratio

Latest as of June 2020: 0.06x

Prostatype Genomics AB (PROGEN) has a Capital Reinvestment Ratio of 0.06x as of June 2020, meaning it reinvests 0% of its operating cash flow (Skr5.63 Million) in capital expenditures (Skr361.71K). See PROGEN cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.06x

Capex / Operating Cash Flow

Operating Cash Flow

Skr5.63 Million

SEK

Capital Expenditures

Skr361.71K

SEK

Data as of

Jun 2020

Most recent filing

Annual Capital Reinvestment Ratio for Prostatype Genomics AB (None–None)

Year-by-year Capital Reinvestment Ratio for Prostatype Genomics AB from None to None. For live market cap and broader valuation context, see Prostatype Genomics AB stock valuation.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow